[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:atypical-teratoid-rhabdoid-tumor":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":87,"states":88},"Atypical Teratoid\u002FRhabdoid Tumor",12,9,[8,16,22,29,35,42,48,54,61,67,74,80],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07447076","Study of Novel Therapies for Young People With Recurrent\u002FProgressive Atypical Teratoid Rhabdoid Tumor (ATRT)",[12],"Phase 2","RECRUITING","2026-08-26T02:15:36.077529Z","2026-05-05T02:43:29.727119Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT01356290","Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors",[12],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.166226Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT03911388","HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors",[26],"Phase 1","2026-08-26T02:16:16.169331Z","2026-07-30T01:46:14.458417Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06193759","Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)",[26],"2026-08-26T02:18:25.327036Z","2026-06-17T21:13:38.320470Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT06465199","Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas",[39],"Phase 1\u002FPhase 2","2026-08-26T02:15:58.452248Z","2026-06-16T05:54:07.918391Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT04185038","Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma\u002FDiffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors",[26],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:28.903254Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07087002","GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults",[26],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:28.714199Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT07017816","A Phase 0\u002F1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.",[58],"Early Phase 1","2026-08-26T02:17:32.059863Z","2026-05-05T02:43:27.319544Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT04099797","C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)",[26],"2026-08-26T02:16:22.235886Z","2026-05-05T02:43:27.089113Z",{"nct_id":68,"title":69,"phases":70,"status":71,"updated_at":72,"content_modified":73},"NCT07513194","GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)",[26],"NOT_YET_RECRUITING","2026-08-26T02:17:47.813245Z","2026-05-05T02:43:27.948756Z",{"nct_id":75,"title":76,"phases":77,"status":71,"updated_at":78,"content_modified":79},"NCT07390539","B7-H3.CD28Z.CART in CNS Neoplasms",[26],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:29.514138Z",{"nct_id":81,"title":82,"phases":83,"status":84,"updated_at":85,"content_modified":86},"NCT05835687","Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors",[26],"ACTIVE_NOT_RECRUITING","2026-08-03T03:23:28.660374Z","2026-05-05T02:43:27.753658Z",[],[89],{"state":90,"count":91,"slug":92},"Texas",5,"texas"]